Literature DB >> 29361320

Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (Gesepoc): The Epoconsul Study.

Myriam Calle Rubio1, Juan Luis Rodríguez Hermosa2, Juan José Soler-Cataluña3, José Luis López-Campos4, Bernardino Alcazar Navarrete5, Joan B Soriano6, José Miguel Rodríguez Gónzalez-Moro7, Manuel E Fuentes Ferrer8, Marc Miravitlles9.   

Abstract

INTRODUCTION: EPOCONSUL is the first national audit to analyze medical care for COPD in pulmonology departments in Spain. The main objective was to perform a retrospective analysis to determine the distribution of GesEPOC 2017 COPD risk levels and to evaluate clinical activity according to the new recommendations.
MATERIAL AND METHODS: This is a cross-sectional clinical audit in which consecutive COPD cases were recruited over one year. The study evaluated risk and clinical phenotype according to GesEPOC 2017, and their correlation with the clinical interventions employed.
RESULTS: The most common risk category was high risk (79.8% versus 20.2%; p < 0.001), characterized by a higher level of severity on BODE and BODEx indexes, and a higher comorbidity burden. The most common phenotype was non-exacerbator. The most commonly used treatment in low-risk patients was bronchodilator monotherapy (34.8%) and triple therapy in high-risk patients (53.7%). High risk was most frequently characterized by phenotype (57.6% versus 52%; p = 0.014) and pulmonary function test results: lung volume (47.7% versus 35.8%; p < 0.001), lung diffusion (51.4% versus 42.1%; p < 0.001) and walk test (37.8% versus 15.8%; p < 0.001).
CONCLUSIONS: Most patients treated in pulmonology departments were high-risk and non-exacerbator phenotype. Clinical interventions differed according to risk level and mainly followed GesEPOC recommendations, although there is significant room for improvement.
Copyright © 2017 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Clinical phenotype; Enfermedad pulmonar obstructiva crónica; Fenotipo clínico; GesEPOC; Nivel de riesgo; Risk level

Mesh:

Substances:

Year:  2018        PMID: 29361320     DOI: 10.1016/j.arbres.2017.11.015

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  13 in total

1.  Effectiveness of an Intervention to Improve Management of COPD using the AUDIT Methodology: Results of the Neumo-Advance Study.

Authors:  Javier de Miguel-Díez; Rodrigo Jiménez-García; Ana López de Andrés; Fernando Zaragoza Arnáez
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

2.  Pulmonologists' Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey.

Authors:  Marc Miravitlles; Fernando González-Torralba; Cristina Represas-Represas; Xavier Pomares; Eduardo Márquez-Martín; Cruz González; Carlos Amado; Carles Forné; Soledad Alonso; Bernardino Alcázar; Miriam Barrecheguren; Juan María Jurado Mirete; Elsa Naval
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-12

3.  Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit.

Authors:  Myriam Calle Rubio; Juan José Soler-Cataluña; José Luis López-Campos; Bernardino Alcázar Navarrete; José Miguel Rodríguez González-Moro; Joan B Soriano; Manuel E Fuentes Ferrer; Juan Luis Rodriguez Hermosa
Journal:  PLoS One       Date:  2019-02-06       Impact factor: 3.240

4.  Triple therapy for COPD: a crude analysis from a systematic review of the evidence.

Authors:  Jose Luis Lopez-Campos; Laura Carrasco-Hernandez; Esther Quintana-Gallego; Carmen Calero-Acuña; Eduardo Márquez-Martín; Francisco Ortega-Ruiz; Joan B Soriano
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

5.  Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD.

Authors:  Juan Luis Rodríguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Alvarez-Sala; Myriam Calle Rubio
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-08

6.  Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.

Authors:  Helgo Magnussen; Sarah Lucas; Therese Lapperre; Jennifer K Quint; Ronald J Dandurand; Nicolas Roche; Alberto Papi; David Price; Marc Miravitlles
Journal:  Respir Res       Date:  2021-01-21

7.  Predictors of Single Bronchodilation Treatment Response for COPD: An Observational Study with the Trace Database Cohort.

Authors:  Laura Carrasco Hernández; Candela Caballero Eraso; Borja Ruiz-Duque; María Abad Arranz; Eduardo Márquez Martín; Carmen Calero Acuña; Jose Luis Lopez-Campos
Journal:  J Clin Med       Date:  2021-04-15       Impact factor: 4.241

8.  Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD.

Authors:  Marc Miravitlles; Alicia Marín; Alicia Huerta; David Carcedo; Alba Villacampa; Jaume Puig-Junoy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10

9.  Compliance and Utility of a Smartphone App for the Detection of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Cohort Study.

Authors:  Juan Luis Rodriguez Hermosa; Antonia Fuster Gomila; Luis Puente Maestu; Carlos Antonio Amado Diago; Francisco Javier Callejas González; Rosa Malo De Molina Ruiz; Manuel E Fuentes Ferrer; Jose Luis Álvarez Sala-Walther; Myriam Calle Rubio
Journal:  JMIR Mhealth Uhealth       Date:  2020-03-19       Impact factor: 4.773

10.  Health-related quality of life of patients diagnosed with COPD in Extremadura, Spain: results from an observational study.

Authors:  María Merino; Renata Villoro; Álvaro Hidalgo-Vega; Concepción Carmona
Journal:  Health Qual Life Outcomes       Date:  2019-12-30       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.